JP Morgan Chase
AVIR icon

JP Morgan Chase’s Atea Pharmaceuticals AVIR Stock Holding History

JP Morgan Chase’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$70K – 6629
2021
Q3 		$70K Buy
+2,000
New +$55.5K ﹤0.01% 5726

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's AVIR Position: Q2 2026 in Review

JP Morgan Chase increased its Atea Pharmaceuticals (AVIR) stake by 0.61% in Q2 2026, buying an estimated $28.7K and bringing the position to 945,918 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3574.

JP Morgan Chase first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $4.81M in Q4 2025. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • JP Morgan Chase held 945,918 shares of Atea Pharmaceuticals worth $4.36M as of Q2 2026.
  • JP Morgan Chase bought 5,761 Atea Pharmaceuticals shares in Q2 2026, an estimated $28.7K.
  • Atea Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3574 holding.
  • JP Morgan Chase first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Atea Pharmaceuticals position peaked at $4.81M in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.